VTAK Stock Summary and Trading Ideas (Catheter Precision | AMEX:VTAK)

Catheter Precision Inc is engaged in design, manufacture and sale of new and innovative medical technologies primarily focused in the field of cardiac electrophysiology, or EP. The Company's primary product is the View into Ventricular Onset System (VIVO or VIVO System), which is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. The VIVO system has achieved a CE Mark allowing it to be commercialized in the European Union and has been placed at several hospitals in Europe. Its newest product, the Surgical Vessel Closing Pressure Device (LockeT), is a suture retention device indicated for wound healing by distributing suture tension.

Catheter Precision trades on the AMEX stock market under the symbol VTAK.

As of February 2, 2026, VTAK stock price declined to $1.91 with 13,455 million shares trading.

VTAK has a beta of 1.33, meaning it tends to be more sensitive to market movements. VTAK has a correlation of 0.01 to the broad based SPY ETF.

VTAK has a market cap of $3.19 million. This is considered a Sub-Micro Cap stock.

VTAK has outperformed the market in the last year with a return of +365.5%, while the SPY ETF gained +16.4%. However, in the most recent history, VTAK shares have underperformed the stock market with its stock returning -20.4% in the last 3 month period and -10.3% for the last 2 week period, while SPY has returned +2.8% and +0.7%, respectively.

VTAK support price is $1.83 and resistance is $2.06 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VTAK shares will trade within this expected range on the day.